This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the diabetes-and-obesity pharmaceutical leader, brought Anthropic's Claude into its drug-research workflow, Reuters reported Wednesday. The U.S. depositary shares traded at $42.125. Novo will begin by testing Claude Science on selected scientific questions while also deploying Anthropic models for software-development work. Warning! GuruFocus has detected 4 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator.NVO GF Value chart The partnership is about speed, not AI headlines. Novo and Anthropic want the models to sharpen biological reasoning and compress the time researchers spend moving from an idea to an actionable scientific decision.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.